Table 1.

Characteristics of studies included in the meta-analysis.

Surname	Year	Country	Ethnicity	Cancer type	Control source	Genotype method	Number of cases				Number of controls				MAF
							All	GG	GC	CC	All	GG	GC	CC
Knappskog et al. [13]	2011	Norway and Dutch	Caucasian	Breast	PB	PCR-sequencing	1,973	1,843	130	0	2,518	2,322	196	0	0.039
Knappskog et al. [13]	2011	Norway and Dutch	Caucasian	Ovarian	PB	PCR-sequencing	832	782	50	0	2,518	2,322	196	0	0.039
Paulin et al. [14]	2008	Scotland	Caucasian	Breast	PB	PCR-sequencing	299	278	18	3	275	263	12	0	0.022
Bjørnslett et al. [15]	2012	Norway	Caucasian	Ovarian	PB	PCR-sequencing	1,566	1,471	92	3	2,465	2,274	183	8	0.040
Knappskog et al. [16]	2012	Norway	Caucasian	Endometrial	PB	PCR-sequencing	910	846	63	1	2,465	2,274	183	8	0.040
Knappskog et al. [16]	2012	Norway	Caucasian	Prostate	PB	PCR-sequencing	666	608	55	3	675	623	51	1	0.039
Piotrowski et al. [17]	2012	Poland	Caucasian	Breast	PB	Sequencing	468	444	23	1	550	494	54	2	0.053
Ryan et al. [18]	2012	USA	African	Lung	PB	Taqman	142	139	3	0	253	250	3	0	0.006
Ryan et al. [18]	2012	USA	Caucasian	Lung	PB	Taqman	373	351	21	1	398	373	25	0	0.031
Rebbani et al. [19]	2014	Morocco	Mixed	HCC	PB	PCR-sequencing	119	115	4	0	103	101	2	0	0.010
Vargas-Torres et al. [20]	2014	Brazil	Mixed	Cervical	HB	PCR-RFLP	293	288	5	0	184	184	0	0	NA
Gansmo et al. [21]	2015	Norway	Caucasian	Colon	PB	LightSNiP	1,532	1,430	99	3	3,749	3,495	254	0	0.034
Gansmo et al. [21]	2015	Norway	Caucasian	Lung	PB	LightSNiP	1,331	1,232	98	1	3,749	3,495	254	0	0.034
Gansmo et al. [21]	2015	Norway	Caucasian	Breast	PB	LightSNiP	1,717	1,614	100	3	1,872	1,750	122	0	0.033
Gansmo et al. [21]	2015	Norway	Caucasian	Prostate	PB	LightSNiP	2,501	2,319	175	7	1,877	1,745	132	0	0.035
Roszak et al. [22]	2015	Poland	Caucasian	Cervical	HB	Sanger sequencing	456	430	25	1	481	431	47	3	0.055

HB: hospital-based; PB, population-based; PCR-RFLP: polymerase chain reaction-restriction fragment length polymorphism; HCC: hepatocellular carcinoma; MAF: Minor Allele Frequency; NA: not applicable.